申请人:Kissei Pharmaceutical Co.
公开号:US04374845A1
公开(公告)日:1983-02-22
The imidazole derivatives of the general formula: ##STR1## (wherein R.sup.1 represents a hydrogen atom or straight- or branched-chain alkyl group of 1 to 4 carbon atoms), or pharmaceutically acceptable non-toxic salts thereof, which have a specifically inhibitory effect on the biosynthesis of thromboxane A.sub.2 (abbreviated as TXA.sub.2 hereafter) and are, therefore, useful as treating agents for disease caused by TXA.sub.2 such as inflammation, cerebral apoplexy, miocardial infarction, acute cardiac death, cardiostenosis and thrombus etc.
通式为:##STR1##的咪唑衍生物(其中R.sup.1代表氢原子或1至4个碳原子的直链或支链烷基),或其药用可接受的无毒盐,对血栓素A.sub.2(以下简称为TXA.sub.2)的生物合成具有特异性抑制作用,因此可用作治疗由TXA.sub.2引起的疾病,如炎症、脑卒中、心肌梗死、急性心脏死亡、心脏狭窄和血栓等。